TACTI-004 trial

Business news, market intelligence, and global industry analysis.

The Latest

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Representative image of a Boeing C-17 Globemaster III during maintenance, illustrating Boeing’s $166.8 million landing gear spares contract modification and the growing strategic importance of military airlift sustainment.

Why Boeing’s $166.8 m C-17 spares win could matter more than it looks for BA stock

Why selective immune homeostasis is the bigger story behind CUE-401

Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt

Why Immutep Limited halted its lung cancer trial and how the decision reshapes its immunotherapy strategy (NASDAQ: IMMP)

Immutep Limited halts the TACTI-004 Phase III lung cancer trial. Discover what the futility result means for eftilagimod alfa and LAG-3 immunotherapy.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 16, 2026